Pharmacyclics, Inc.

Edison Pharmaceuticals, Inc.

Bioelectron Technology Corporation

Ptc Therapeutics, Inc.

Axys Pharmaceuticals, Inc.

Reiley Pharmaceuticals, Inc.

William Dvorak Shrader

Kieron E Wesson

Orion D Jankowski

Paul Mollard

Roopa Rai

Andrew W Hinman

Aleksandr Kolesnikov

Wendy B Young

Steven M Torkelson

Daniel A Dickman

Dana Davis

Dange Vijay Kumar

Colin O'Bryan

Mark A Reiley

Julio Cesar Medina

Frank Kayser

Erik Joel Verner

Viktoria Kheifets

Richard L Mackman

Christopher R Cornell

B Michael Silber

Edgar P Lee

Darin A Allen

Jason M Hataye

Witold N Hruzewicz

Spencer R Jeffrey

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinoly)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, an well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

Disclosed herein are phenazine-3-one and phenothiazine-3-one derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.

Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders

Conjugates derived from non-steroidal anti-inflammatory drugs (NSAIDs) and methods of use thereof are disclosed, useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The NSAID-based conjugates contain an imaging moiety. The conjugates concentrate at sites of increased cyclooxygenase expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections.

Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging

Disclosed herein are resorufin derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. 

Resorufin derivatives for treatment of oxidative stress disorders

Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compound is a compound of Formula I or Formula II: wherein: Rand Rare independently hydrogen, (C-C)alkyl or &#x2014;O(C-C)alkyl; or Rand Rtogether represent &#x2014;CH&#x2550;CH&#x2014;CH&#x2550;CH&#x2014;; Ris (C1-C6)alkyl; X is &#x2014;CH&#x2550;CH&#x2014; or &#x2014;C&#x2261;C&#x2014;; m is 1-10; n is 1-5; k is 1-3, with the proviso that when k is an integer of 2 or 3, n is independently 1-5 in each occurrence of the &#x2014;X&#x2014;(CH)&#x2014; group; Y is &#x2014;OR, &#x2014;CN, &#x2014;C(&#x2550;O)OR, &#x2014;C(&#x2550;O)R, or &#x2014;C(&#x2550;O)N(R); Rand Rare independently selected from the group consisting of hydrogen, &#x2014;(C-C)alkyl, &#x2014;(C-C)haloalkyl, &#x2014;C(&#x2550;O)&#x2014;(C-C)alkyl, &#x2014;C(&#x2550;O)&#x2014;(C-C)haloalkyl, &#x2014;C(&#x2550;O)&#x2014;NH(C-C)alkyl, &#x2014;C(&#x2550;O)&#x2014;N((C-C)alkyl), &#x2014;C(&#x2550;O)&#x2014;NH, and phenyl, wherein the phenyl group may optionally be substituted with a substituent selected from the group consisting of &#x2014;(C-C)alkyl, &#x2014;O&#x2014;(C-C)alkyl, &#x2014;(C-C)haloalkyl, and halo; each Ris independently hydrogen or &#x2014;(C-C)alkyl; and M is &#x2014;H, &#x2014;C(O)&#x2014;Ror &#x2014;C(O)O&#x2014;R, wherein Ris &#x2014;(C-C)alkyl or phenyl; or a stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, crystalline form, non-crystalline form, hydrate or solvate thereof. 

Benzoquinone derivatives for treating oxidative stress disorders

Disclosed herein are resorufin derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.

Factor VIIa inhibitor

[object Object]

Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-substituted-p-quinone derivatives as disclosed herein.

2-(2-hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors

Growing community of inventors

Belmont, CA, United States of America

William Dvorak Shrader